ArticleMicrobial cell factories2026
Whole-cell surface-display system in attenuated Salmonella Enteritidis for slide microagglutination-based antibody detection.
Article in Microbial cell factories, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroagglutination is a sensitive, rapid, and cost-effective serological assay widely used for disease diagnosis and surveillance in animals and humans. However, it traditionally relies on culturing live pathogenic bacteria as antigens, posing biosafety risks and limiting its application primarily to bacterial pathogens. Bacterial surface display technology offers a promising alternative by enabling the presentation of heterologous proteins or peptides on the bacterial surface, avoiding the need to culture the target pathogen, simplifying antigen preparation, and enabling potential diagnostic applications for non-bacterial pathogens. Despite these advantages, integration of this technology with slide-based microagglutination assays has not yet been evaluated. In this proof-of-concept, we evaluated a surface display platform in attenuated Salmonella Enteritidis for antibody detection by slide microagglutination, using the nucleocapsid (N) protein of Infectious Bronchitis Virus (IBV) as a model antigen.
resultsThe IBV N protein was fused to the N-terminal anchor domain of the ice nucleation protein (INP) and cloned into pET-28a. The resulting INP_N fusion protein was expressed in attenuated Salmonella Enteritidis, and its surface exposure was evaluated by immunofluorescence and flow cytometry on non-permeabilized cells, with flow cytometry indicating a surface display efficiency of 96.5%. Slide microagglutination was performed using 50 hen sera and inactivated Salmonella Enteritidis cells presenting surface-exposed N protein. This assay identified all positive sera and 20 of 25 negative sera, showing substantial agreement with the reference ELISA (κ = 0.8), with preliminary estimates of 100% sensitivity (95% CI, 87-100%) and 80% specificity (95% CI, 61-91%). No cross-reactivity was observed with commercial antisera against pathogens unrelated to IBV.
conclusionsThe attenuated Salmonella surface-display platform integrated into a slide microagglutination assay showed preliminary feasibility for antibody detection under the conditions evaluated. This approach does not require live pathogen cultivation, specialized equipment, antigen purification, or chemical conjugation steps. However, further optimization is needed to improve the platform's display efficiency and enhance specificity without compromising sensitivity. In addition, evaluation using a larger and more diverse sample set, including field samples, is required to further assess the performance and potential applicability of the assay.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.